Evidence for the appearance of novel gene products during amphibian blastulation

Genetic information begins to be transcribed during early cleavage in amphibian embryos,(1,2) and the tempo of informational RNA synthesis increases gradually through cleavage and into the early blastula stage. Previous studies from this laboratory (3,4) have shown that at this point a remarkable, near embryo-wide acceleration of informational RNA synthesis occurs, resulting during the mid-tolate blastular period in at least a 20-fold increase in the rate of synthesis of heterogeneously sedimenting, DNA-like RNA

Genomic function during the lampbrush chromosome stage of amphibian oogenesis

Throughout its lengthy developmental history the disposition of the genetic material in the amphibian oocyte nucleus differs from that in other cell types. The chromosomes in the oocyte nucleus, arrested for the whole of oogenesis at the prophase of the first meiotic division, are known to contain at least the tetraploid amount of DNA.(1,2) Oogenesis in amphibia requires months or even years to complete, depending on the species

A história da certificação ISO 9001 da Embrapa Meio Ambiente.

bitstream/item/40190/1/Documentos-84.pd

Therapeutical use of the cannabinoids in psychiatry

OBJETIVO: Revisar os principais avanços no potencial uso terapêutico de alguns compostos canabinoides em psiquiatria. MÉTODO: Foi realizada busca nos bancos de dado PubMed, SciELO e Lilacs e identificados estudos e revisões da literatura sobre o uso terapêutico dos canabinoides em psiquiatria, em particular canabidiol, rimonabanto, Δ9-tetraidrocanabinol e seus análogos. RESULTADOS: O canabidiol demonstrou apresentar potencial terapêutico como antipsicótico, ansiolítico, antidepressivo e em diversas outras condições. O Δ9-tetraidrocanabinol e seus análogos demonstraram efeitos ansiolíticos, na dependência de cannabis, bem como adjuvantes no tratamento de esquizofrenia, apesar de ainda carecerem de mais estudos. O rimonabanto demonstrou eficácia no tratamento de sintomas subjetivos e fisiológicos da intoxicação pela cannabis e como adjuvante no tratamento do tabagismo. Os potenciais efeitos colaterais, de induzir depressão e ansiedade limitaram o uso clínico deste antagonista CB1. CONCLUSÃO: Os canabinoides têm demonstrado que podem ter amplo interesse terapêutico em psiquiatria, porém mais estudos controlados são necessários para confirmar estes achados e determinar a segurança destes compostos.OBJECTIVE: To review the main advances related to the potential therapeutic use of cannabinoid compounds in psychiatry. METHOD: A search was performed in the online databases PubMed, ScieELO, and Lilacs for studies and literature reviews concerning therapeutic applications of cannabinoids in psychiatry, especially cannabidiol, rimonabant, Δ9-tetrahydrocannabinol, and their analogues. RESULTS: Cannabidiol was found to have therapeutic potential with antipsychotic, anxiolytic, and antidepressant properties, in addition to being effective in other conditions. Δ9-tetrahydrocannabinol and its analogues were shown to have anxiolytic effects in the treatment of cannabis dependence and to function as an adjuvant in the treatment of schizophrenia, although additional studies are necessary to support this finding. Rimonabant was effective in the treatment of the subjective and physiological symptoms of cannabis intoxication and functioned as an adjuvant in the treatment of tobacco addiction. The potential to induce adverse reactions such as depression and anxiety restrained the clinical use of this CB1 antagonist. CONCLUSION: Cannabinoids may be of great therapeutic interest to psychiatry; however, further controlled trials are necessary to confirm the existing findings and to establish the safety of such compounds